Saverio Minucci

List of Publications by Year
in descending order

70 papers	15,350 citations	136950 32 h-index	95266 68 g-index
74 all docs	74 docs citations	74 times ranked	28805 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
3	Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Reviews Cancer, 2006, 6, 38-51.	28.4	2,049
4	Fusion proteins of the retinoic acid receptor-Î± recruit histone deacetylase in promyelocytic leukaemia. Nature, 1998, 391, 815-818.	27.8	1,015
5	Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription Factor. Science, 2002, 295, 1079-1082.	12.6	754
6	HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature, 2011, 471, 74-79.	27.8	368
7	Oligomerization of RAR and AML1 Transcription Factors as a Novel Mechanism of Oncogenic Activation. Molecular Cell, 2000, 5, 811-820.	9.7	273
8	Biochemical, Structural, and Biological Evaluation of Tranylcypromine Derivatives as Inhibitors of Histone Demethylases LSD1 and LSD2. Journal of the American Chemical Society, 2010, 132, 6827-6833.	13.7	261
9	Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3Î²-MCL-1 Axis. Cancer Cell, 2019, 35, 798-815.e5.	16.8	212
10	Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia. British Journal of Cancer, 2016, 114, 605-611.	6.4	210
11	Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?. Oncogene, 2001, 20, 3110-3115.	5.9	191
12	Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nature Communications, 2017, 8, 593.	12.8	175
13	Activation of a promyelocytic leukemiaâ€“tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nature Medicine, 2014, 20, 167-174.	30.7	166
14	A comprehensive review of lysine-specific demethylase 1 and its roles in cancer. Epigenomics, 2017, 9, 1123-1142.	2.1	125
15	Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion. Nature Communications, 2015, 6, 10044.	12.8	108
16	c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer. Clinical Cancer Research, 2017, 23, 2542-2555.	7.0	105
17	PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood, 2002, 100, 2989-2995.	1.4	103
18	Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood, 2021, 137, 3093-3104.	1.4	91

#	Article	IF	Citations
19	Common themes in the pathogenesis of acute myeloid leukemia. Oncogene, 2001, 20, 5680-5694.	5.9	72
20	Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent. Journal of Medicinal Chemistry, 2016, 59, 1501-1517.	6.4	70
21	Beclin 1 restrains tumorigenesis through Mcl-1 destabilization in an autophagy-independent reciprocal manner. Nature Communications, 2014, 5, 5637.	12.8	65
22	Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 2: Structure-Based Drug Design and Structureâ€“Activity Relationship. Journal of Medicinal Chemistry, 2017, 60, 1693-1715.	6.4	60
23	In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype. Cancer Discovery, 2016, 6, 650-663.	9.4	59
24	Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 1: High-Throughput Screening and Preliminary Exploration. Journal of Medicinal Chemistry, 2017, 60, 1673-1692.	6.4	59
25	Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acidâ€“induced differentiation. Science Advances, 2020, 6, eaax2746.	10.3	56
26	Entinostat for the treatment of breast cancer. Expert Opinion on Investigational Drugs, 2017, 26, 965-971.	4.1	54
27	Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: A novel class of irreversible inhibitors of histone demethylase KDM1A. European Journal of Medicinal Chemistry, 2014, 86, 352-363.	5.5	50
28	Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. Blood, 2015, 126, 2392-2403.	1.4	48
29	Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors. European Journal of Medicinal Chemistry, 2018, 155, 316-336.	5.5	46
30	Epigenetic therapies in haematological malignancies: Searching for true targets. European Journal of Cancer, 2009, 45, 1137-1145.	2.8	45
31	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. Clinical Cancer Research, 2021, 27, 4311-4324.	7.0	44
32	Pathology Tissue-quantitative Mass Spectrometry Analysis to Profile Histone Post-translational Modification Patterns in Patient Samples. Molecular and Cellular Proteomics, 2016, 15, 866-877.	3.8	41
33	Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells. European Journal of Medicinal Chemistry, 2019, 165, 80-92.	5.5	34
34	Extensive and systematic rewiring of histone post-translational modifications in cancer model systems. Nucleic Acids Research, 2018, 46, 3817-3832.	14.5	31
35	Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blasts. European Journal of Medicinal Chemistry, 2015, 94, 163-174.	5.5	28
36	Synthetic Lethality Triggered by Combining Olaparib with BRCA2â€“Rad51 Disruptors. ACS Chemical Biology, 2017, 12, 2491-2497.	3.4	28

#	Article	IF	Citations
37	Functional characterization of a novel FGFR1OPâ€RET rearrangement in hematopoietic malignancies. Molecular Oncology, 2014, 8, 221-231.	4.6	27
38	Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors. European Journal of Medicinal Chemistry, 2016, 108, 53-67.	5.5	26
39	From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib. Frontiers in Pharmacology, 2017, 8, 718.	3.5	23
40	PAT-ChIP coupled with laser microdissection allows the study of chromatin in selected cell populations from paraffin-embedded patient samples. Epigenetics and Chromatin, 2014, 7, 18.	3.9	22
41	Long nonâ€coding RNA TINCR suppresses metastatic melanoma dissemination by preventing ATF4 translation. EMBO Reports, 2021, 22, e50852.	4.5	21
42	Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition. Haematologica, 2020, 105, 2105-2117.	3.5	20
43	Single cell-derived spheroids capture the self-renewing subpopulations of metastatic ovarian cancer. Cell Death and Differentiation, 2022, 29, 614-626.	11.2	20
44	Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: From bench to bedside. Cancer Treatment Reviews, 2015, 41, 754-760.	7.7	19
45	Self-renewal of tumor cells: epigenetic determinants of the cancer stem cell phenotype. Current Opinion in Genetics and Development, 2016, 36, 92-99.	3.3	18
46	LSD1-directed therapy affects glioblastoma tumorigenicity by deregulating the protective ATF4-dependent integrated stress response. Science Translational Medicine, 2021, 13, eabf7036.	12.4	18
47	Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 575-581.	3.3	17
48	Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML. Oncogene, 2022, 41, 878-894.	5.9	17
49	Pure Diastereomers of a Tranylcypromine-Based LSD1 Inhibitor: Enzyme Selectivity and In-Cell Studies. ACS Medicinal Chemistry Letters, 2015, 6, 173-177.	2.8	16
50	Epigenomic profiling of archived FFPE tissues by enhanced PAT-ChIP (EPAT-ChIP) technology. Clinical Epigenetics, 2018, 10, 143.	4.1	16
51	Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models. European Journal of Medicinal Chemistry, 2022, 237, 114410.	5.5	15
52	Quantitative Chemical Proteomics Identifies Novel Targets of the Anti-cancer Multi-kinase Inhibitor E-3810. Molecular and Cellular Proteomics, 2014, 13, 1495-1509.	3.8	14
53	SMARCA5 interacts with NUP98-NSD1 oncofusion protein and sustains hematopoietic cells transformation. Journal of Experimental and Clinical Cancer Research, 2022, 41, 34.	8.6	14
54	Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer. Antioxidants and Redox Signaling, 2015, 23, 15-29.	5.4	13

#	Article	IF	Citations
55	Fish the ChIPs: a pipeline for automated genomic annotation of ChIP-Seq data. Biology Direct, 2011, 6, 51.	4.6	12
56	Determinants of Oncogenic Transformation in Acute Promyelocytic Leukemia: The Hetero-Union Makes the Force. Cancer Cell, 2007, 12, 1-3.	16.8	11
57	The Role of Chromatin-Associated Proteins in Cancer. Annual Review of Cancer Biology, 2017, 1, 355-377.	4.5	10
58	MicroRNA-222 Regulates Melanoma Plasticity. Journal of Clinical Medicine, 2020, 9, 2573.	2.4	10
59	Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia. Bioorganic and Medicinal Chemistry, 2022, 56, 116596.	3.0	8
60	Comparing apples with oranges: Studying LSD1 inhibitors in cellular assays. Pharmacological Research, 2019, 146, 104345.	7.1	7
61	Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside. European Journal of Cancer, 2019, 122, 22-41.	2.8	7
62	Mass-spectrometry analysis of histone post-translational modifications in pathology tissue using the PAT-H-MS approach. Data in Brief, 2016, 7, 188-194.	1.0	6
63	Endosomal trafficking and DNA damage checkpoint kinases dictate survival to replication stress by regulating amino acid uptake and protein synthesis. Developmental Cell, 2021, 56, 2607-2622.e6.	7.0	6
64	Indolin-2-one derivatives as selective Aurora B kinase inhibitors targeting breast cancer. Bioorganic Chemistry, 2021, 117, 105451.	4.1	6
65	Novel potent inhibitors of the histone demethylase KDM1A (LSD1), orally active in a murine promyelocitic leukemia model. Future Medicinal Chemistry, 2017, 9, 1161-1174.	2.3	4
66	Anticancer innovative therapy congress: Highlights from the 10th anniversary edition. Cytokine and Growth Factor Reviews, 2021, 59, 1-8.	7.2	4
67	Tackling Oxidative Stress by a Direct Route: A New Job for HDAC Inhibitors?. Chemistry and Biology, 2015, 22, 431-432.	6.0	2
68	DNA binding modes of leukemia oncoproteins. Blood, 2016, 127, 177-178.	1.4	2
69	Prognostic and predictive role of fumarate hydratase in metastatic clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 617-617.	1.6	0
70	Fumarate hydratase expression in localized, radically-resected clear cell renal cell carcinoma and its association with clinical outcomes.. Journal of Clinical Oncology, 2019, 37, 620-620.	1.6	0